Akebia Therapeutics, Inc.: Series B $22M

Posted in I - Series B, Q - 2Q11, R - MID WEST, X - Anemia, X - Vascular, XX - OH

Akebia Therapeutics (Cincinnati, OH) a clinical-stage pharmaceutical focused on anemia and vascular disorders, closed a $22M Series B financing. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem.

Sep

2009

Akebia Therapeutics, Inc.: Series A $16M

Posted in I - Series A, Q - 3Q09, R - MID WEST, X - Anemia, X - Vascular, XX - OH

Akebia Therapeutics (Cincinnati, OH) a clinical-stage biopharmaceutical company focused on the development of small-molecules for anemia and vascular disease, closed a $16M Series A bringing the total financing to $25M. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital.

Jun

2009

Proteon Therapeutics, Inc.: Series B $12M

Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - Hemodialysis, X - PAD, X - Renal, X - Vascular, XX - MA

Proteon Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on a recombinant human elastase designed to improve arteriovenous fistula surgery outcomes in patients requiring chronic hemodialysis, closed on $12M, bringing the total Series B financing to $50M. Participants include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio, Vectis Healthcare & Life Science Fund, TVM Capital, [...]

Mar

2009

Proteon Therapeutics, Inc.: Series B $38M

Posted in I - Series B, Q - 1Q09, R - NORTH EAST, X - Renal, X - Vascular, XX - MA

Proteon Therapeutics (Waltham, MA) a clinical stage biopharmaceutical company focused on renal and vascular disease, closed a $38M Series B financing. Participants include MPM Capital, Vectis Healthcare & Life Sciences Fund, TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners.

to top of page...